AU2002316795B2 - Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug - Google Patents

Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug Download PDF

Info

Publication number
AU2002316795B2
AU2002316795B2 AU2002316795A AU2002316795A AU2002316795B2 AU 2002316795 B2 AU2002316795 B2 AU 2002316795B2 AU 2002316795 A AU2002316795 A AU 2002316795A AU 2002316795 A AU2002316795 A AU 2002316795A AU 2002316795 B2 AU2002316795 B2 AU 2002316795B2
Authority
AU
Australia
Prior art keywords
neoplastic
cyano
amino
alkoxy
alkoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002316795A
Other languages
English (en)
Other versions
AU2002316795A1 (en
Inventor
Lise Binderup
Erik Bramm
Karin Jexner Hamberg
Pernille-Julia Vig Hjarnaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of AU2002316795A1 publication Critical patent/AU2002316795A1/en
Application granted granted Critical
Publication of AU2002316795B2 publication Critical patent/AU2002316795B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002316795A 2001-05-24 2002-05-24 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug Ceased AU2002316795B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29292801P 2001-05-24 2001-05-24
US60/292,928 2001-05-24
PCT/DK2002/000351 WO2002094322A2 (en) 2001-05-24 2002-05-24 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug

Publications (2)

Publication Number Publication Date
AU2002316795A1 AU2002316795A1 (en) 2003-05-08
AU2002316795B2 true AU2002316795B2 (en) 2007-08-02

Family

ID=23126850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002316795A Ceased AU2002316795B2 (en) 2001-05-24 2002-05-24 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug

Country Status (17)

Country Link
US (1) US20030045515A1 (enExample)
EP (1) EP1411984B1 (enExample)
JP (1) JP2005508857A (enExample)
KR (1) KR20040007607A (enExample)
CN (1) CN1516600A (enExample)
AT (1) ATE394100T1 (enExample)
AU (1) AU2002316795B2 (enExample)
BR (1) BR0209936A (enExample)
CA (1) CA2449442A1 (enExample)
CZ (1) CZ20033189A3 (enExample)
DE (1) DE60226446D1 (enExample)
HU (1) HUP0400024A3 (enExample)
IL (1) IL158821A0 (enExample)
MX (1) MXPA03010691A (enExample)
PL (1) PL366462A1 (enExample)
RU (1) RU2291710C2 (enExample)
WO (1) WO2002094322A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
PL228742B1 (pl) * 2002-05-17 2018-05-30 Leo Pharma As Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie
WO2003097602A1 (en) * 2002-05-17 2003-11-27 Leo Pharma A/S Cyanoguanidine produgs
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050075341A1 (en) * 2003-07-17 2005-04-07 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8053446B2 (en) * 2004-12-22 2011-11-08 Leo Pharma A/S Cyanoguanidine compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ563687A (en) 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
EP1912646A2 (de) * 2005-08-04 2008-04-23 Bayer HealthCare AG KOMBINATIONEN MIT IKK-ß INHIBITOREN
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2010088842A1 (zh) * 2009-02-06 2010-08-12 天津和美生物技术有限公司 含有吡啶基氰基胍的药物组合物及其制备和应用
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
CN108779073A (zh) * 2015-06-23 2018-11-09 凯斯西储大学 用于治疗癌症的组合物和方法
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006770A1 (en) * 1992-09-15 1994-03-31 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) N-cyano-n'-pyridylguanidines as serotonin antagonists
WO1998054141A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054143A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054145A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054144A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054142A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
HU225415B1 (en) * 1996-07-15 2006-11-28 Sankyo Co Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006770A1 (en) * 1992-09-15 1994-03-31 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) N-cyano-n'-pyridylguanidines as serotonin antagonists
WO1998054141A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054143A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054145A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054144A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054142A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors

Also Published As

Publication number Publication date
BR0209936A (pt) 2004-04-06
JP2005508857A (ja) 2005-04-07
DE60226446D1 (de) 2008-06-19
CZ20033189A3 (cs) 2004-12-15
MXPA03010691A (es) 2004-07-01
CA2449442A1 (en) 2002-11-28
RU2003137006A (ru) 2005-04-10
HUP0400024A3 (en) 2007-05-29
EP1411984A2 (en) 2004-04-28
PL366462A1 (en) 2005-02-07
WO2002094322A3 (en) 2004-02-26
WO2002094322A2 (en) 2002-11-28
HUP0400024A2 (hu) 2004-04-28
US20030045515A1 (en) 2003-03-06
RU2291710C2 (ru) 2007-01-20
KR20040007607A (ko) 2004-01-24
EP1411984B1 (en) 2008-05-07
ATE394100T1 (de) 2008-05-15
CN1516600A (zh) 2004-07-28
IL158821A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
EP1411984B1 (en) Combination medicament for treatment of neoplastic diseases which contains cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
AU2002316795A1 (en) Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug
US7807682B2 (en) Pyridyl cyanoguanidine compounds
EA006294B1 (ru) Применение комбинации целекоксиба и гемцитабина в комбинированном способе лечебного воздействия при лечении рака поджелудочной железы
EP2990057B1 (en) Pai-1 inhibitor for use in enhancing the antitumor effect of an antitumor agent in a patient
KR20110053347A (ko) 탈라세미아를 치료하는 방법
JP7016883B2 (ja) リンゴ酸－アスパラギン酸シャトル抑制剤および抗癌剤を有効成分として含有する癌の予防および治療用薬学的組成物
EP4086250A2 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
WO2002094265A1 (en) A method of modulating nf-$g(k)b activity
JP5213852B2 (ja) 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用
US6642215B2 (en) Method of modulating NF-kB activity
CA3017557A1 (en) Combination therapy for proliferative diseases
KR102436309B1 (ko) 암의 예방 또는 치료용 약학적 조성물
RU2739558C2 (ru) Композиция, содержащая экстракт водорослевого протеогликана, и ее применение
KR102687556B1 (ko) 종양 전이를 억제하는 방법
KR102141035B1 (ko) 대장 표적성 염증성 장질환 예방 또는 치료용 조성물
CN110072529B (zh) 包含环索奈德的用于抑制癌症干细胞的生长的组合物
JPWO2015156409A1 (ja) 抗癌剤および副作用軽減剤
KR101800129B1 (ko) 암의 예방 또는 치료용 약학적 조성물
HK1065260A (en) Combination medicament for treatment of neoplastic diseases
JP2013028535A (ja) 分化誘導因子又はその類縁体を含有する抗炎症剤
JP2024521441A (ja) 化学療法関連の胃腸副作用を治療するための化合物及び方法
CN115845049A (zh) 一种治疗黑素瘤的联合用药物组合物及其应用
AU2002308264A1 (en) Novel pyridyl cyanoguanidine compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired